Ultimately, the results underscore a need to re-evaluate how guideline-recommended thresholds influence real-world behavior and to consider strategies that better align diagnostic criteria with ...

Among older adults with established ASCVD, hospitalization for COPD increases risk for ASCVD hospitalization. The risk for atherosclerotic cardiovascular disease (ASCVD) hospitalization after chronic ...

Ohtuvayre (ensifentrine), a drug approved in 2024 to treat chronic obstructive pulmonary disorder (COPD), is receiving high marks from doctors and patients. Ohtuvayre is the first new inhaled COPD ...

Accordingly, the CAT score can be a useful marker in clinical trials that evaluate the effectiveness of treatments in prevention or management of COPD exacerbations, or that investigate the ...

The most impressive randomized controlled trial included in this analysis examined the effect of adding corticosteroids to standard care in 147 patients discharged after treatment for acute COPD.

GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial. The headline ...

UK-based Verona Pharma has scored a key win in a phase 3 trial of its chronic obstructive pulmonary disease (COPD) drug ensifentrine, setting up regulatory filings in the first half of next year.

Have a question about this project? Sign up for a free GitHub account to open an issue and contact its maintainers and the community.

The study, published in Nicotine & Tobacco Research, confirms the link between e-cigarette use and chronic obstructive pulmonary disease (COPD). This counteracts some claims that e-cigarettes are the ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...